Suzhou Teligene
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.
Oncology
Technology Platform
Computer-aided drug design (CADD) platform focused on developing small molecule inhibitors with engineered blood-brain barrier penetration for treating primary and metastatic brain tumors.
Opportunities
Major growth opportunities include demonstrating clinical proof-of-concept in treating brain metastases, a high-unmet need, and leveraging U.S.
regulatory pathways for global development and partnership deals.
Risk Factors
Key risks include clinical trial failures in a competitive targeted therapy landscape, potential safety issues with brain-penetrant compounds, and reliance on funding to advance a broad early-stage pipeline.
Competitive Landscape
Faces competition from large pharma and biotechs in EGFR, HER2, and NTRK spaces (e.g., AstraZeneca, Daiichi Sankyo, Roche, Bayer/Loxo), but differentiates through a specialized focus on CNS penetration and targeting rare EGFR mutations.